Efficacy of intracoronary erythropoietin delivery before reperfusion―gauging infarct size in patients with acute ST-segment elevation myocardial infarction (ICEBERG)

International Heart Journal

Volumn 60, Issue 2, 2019, Pages 255-263

  Seo, Won Woo ^a   Suh, Jung Won ^b   Oh, Il Young ^b   Yoon, Chang Hwan ^b   Cho, Young Seok ^b   Youn, Tae Jin ^b   Chae, In Ho ^b   Choi, Dong Ju ^b  

^a Kangdong Sacred Heart Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Darbepoetin alfa; Left ventricle remodeling

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE MB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; RECOMBINANT ERYTHROPOIETIN; TROPONIN I; ANTIANEMIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD PRESSURE; BRAIN ISCHEMIA; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART MUSCLE ISCHEMIA; HOSPITAL READMISSION; HUMAN; IMPLANTATION; INCIDENCE; LEFT VENTRICLE END DIASTOLIC VOLUME; LEFT VENTRICLE END SYSTOLIC VOLUME; MALE; MYOCARDIAL BLUSH GRADE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; SCORING SYSTEM; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; CARDIAC MUSCLE; CINE MAGNETIC RESONANCE IMAGING; CLINICAL TRIAL; CORONARY BLOOD VESSEL; DRUG EFFECT; DRUG MONITORING; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; INTRAARTERIAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PREOPERATIVE CARE; PROCEDURES; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY VESSELS; DARBEPOETIN ALFA; DRUG MONITORING; FEMALE; HEMATINICS; HUMANS; INFUSIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIUM; PREOPERATIVE CARE; ST ELEVATION MYOCARDIAL INFARCTION; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 85063303473     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/IHJ.18-035     Document Type: Article

References (42)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35.
2. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era. World J Cardiol 2014; 6: 100-6.
3. Fukui Y, Nozawa T, Ihori H, et al. Nicorandil attenuates ischemia-reperfusion injury via inhibition of norepinephrine release from cardiac sympathetic nerve terminals. Int Heart J 2017; 58: 787-93.
4. Wang Y, Wang Q, Yu W, Du H. Crocin attenuates oxidative stress and myocardial infarction injury in rats. Int Heart J 2018; 59: 387-93.
5. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003; 108: 79-85.
6. 6.Rui T, Feng Q, Lei M, et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of ap-1. Cardiovasc Res 2005; 65: 719-27.
7. van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005; 46: 125-33.
8. Suh JW, Chung WY, Kim YS, et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol 2011; 149: 216-20.
9. Ferrario M, Arbustini E, Massa M, et al. High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. Int J Cardiol 2011; 147: 124-31.
10. Voors AA, Belonje AM, Zijlstra F, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010; 31: 2593-600.
11. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol 2009; 104: 1035-40.
12. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention a randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-13.
13. Joy MS. Darbepoetin alfa: A novel erythropoiesis-stimulating protein. Ann Pharmacother 2002; 36: 1183-92.
14. Voils SA, Harpe SH, Brophy GM. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness. Pharmacotherapy 2007; 27: 535-41.
15. Lim GB. Antiplatelet therapy: Intracoronary abciximab during pci for STEMI. Nat Rev Cardiol 2012; 9: 258.
16. Suh JW, Yoon YE, Oh IY, et al. A single-center prospective randomized controlled trial evaluating the safety and efficacy of intracoronary erythropoietin delivery before reperfusion: Gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the ‘ICEBERG Trial’. Contemp Clin Trials 2013; 35: 145-50.
17. Lipšic E, van der Meer P, Voors AA, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20: 135-41.
18. Li J, Xu H, Gao Q, Wen Y. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: A systematic review. Eur J Clin Pharmacol 2012; 68: 469-77.
19. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: Dose response and therapeutic window. Cardiovasc Drugs Ther 2005; 19: 243-50.
20. van‘t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer M-J, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Circulation 1998; 97: 2302-6.
21. Kim D-W, Her S-H, Park M-W, et al. Impact of postprocedural TIMI flow on long-term clinical outcomes in patients with acute myocardial infarction. Int Heart J 2017; 58: 674-85.
22. Schröder R, Dissmann R, Brüggemann T, et al. Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24: 384-91.
23. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27: 1281-92.
24. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000; 101: 2981-8.
25. Yoon CH, Chung WY, Suh JW, et al. Distal protection device aggravated microvascular obstruction evaluated by cardiac MR after primary percutaneous intervention for ST-elevation myocardial infarction. Int J Cardiol 2013; 167: 2002-7.
26. Wright J, Adriaenssens T, Dymarkowski S, Desmet W, Bogaert J. Quantification of myocardial area at risk with T2-weighted CMR: Comparison with contrast-enhanced CMR and coronary angiography. JACC Cardiovasc Imaging 2009; 2: 825-31.
27. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev 1992; 72: 449-89.
28. Brines M, Cerami A. Discovering erythropoietin’s extra-hematopoietic functions: Biology and clinical promise. Kidney Int 2006; 70: 246-50.
29. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004; 109: 2050-3.
30. Hearse D, Humphrey S, Chain E. Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: A study of myocardial enzyme release. J Mol Cell Cardiol 1973; 5: 395-407.
31. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61: 481-97.
32. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006; 48: 176-84.
33. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: Ready for prime-time cardioprotection. Trends Pharmacol Sci 2008; 29: 258-67.
34. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: Reveal: A randomized controlled trial. JAMA 2011; 305: 1863-72.
35. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionclinical perspective: A randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-13.
36. 36.Gao D, Ning N, Niu X, et al. Erythropoietin treatment in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials. Am Heart J 2012; 164: 715-27.e711.
37. Roubille F, Prunier F, Barrère-Lemaire S, et al. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials. Cardiovasc Drugs Ther 2013; 27: 315.
38. Roubille F, Micheau A, Combes S, et al. Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: Results of the randomized Intra-Co-EpoMI trial. Arch Cardiovasc Dis 2013; 106: 135-45.
39. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction. Circulation 2000; 101: 2981-8.
40. Nishiya D, Omura T, Shimada K, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006; 101: 31-9.
41. Wen Y, Xu J, Ma X, Gao Q. High-dose erythropoietin in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs 2013; 13: 435-42.
42. Fokkema ML, Kleijn L, van der Meer P, et al. Long term effects of epoetin alfa in patients with ST-elevation myocardial infarction. Cardiovasc Drugs Ther 2013; 27: 433-9.